ARWR · XBRL financial data

Arrowhead Pharmaceuticals financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ARWR's year ends in late September)

In millions of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Revenue from contracts with customers	88	138	243	241	4	829
Research and development	—	—	—	353	506	607
General and administrative	52	81	124	93	99	124
Total operating expenses	181	287	422	446	605	731
Operating income (loss)	(93)	(149)	(179)	(205)	(601)	98
Interest expense	—	0	0	18	32	89
Other income (expense)	(1)	2	1	2	(2)	5
Income tax expense (benefit)	0	0	4	3	(3)	21
Net income (loss)	(85)	(141)	(176)	(205)	(599)	(2)
Earnings per share, basic USD per share	(0.84)	(1.36)	(1.67)	(1.92)	(5.00)	(0.01)
Earnings per share, diluted USD per share	(0.84)	(1.36)	(1.67)	(1.92)	(5.00)	(0.01)
Weighted average shares, basic millions of shares	101	104	105	107	120	134
Weighted average shares, diluted millions of shares	101	104	105	107	120	134

Fiscal years (ARWR's year ends in late September)

In millions of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	144	184	108	111	103	227
Short-term investments	—	—	—	—	—	693
Marketable securities	85	127	0	293	578	693
Accounts receivable	1	10	1	0	0	7
Total current assets	322	385	405	420	695	951
Property and equipment, net	31	49	110	290	386	383
Right-of-use asset	16	17	58	45	45	44
Total assets	523	710	692	766	1,140	1,385
Accounts payable	7	9	3	36	11	18
Accrued liabilities	5	14	47	40	63	90
Total current liabilities	41	147	139	105	103	195
Lease liability, non-current	20	23	79	105	111	104
Accumulated deficit	(504)	(645)	(821)	(1,026)	(1,626)	(1,627)
Total stockholders' equity	462	409	399	271	185	466
Total liabilities and equity	523	710	692	766	1,140	1,385
Common shares outstanding (cover page) millions of shares	103	105	106	107	124	136

Fiscal years (ARWR's year ends in late September)

In millions of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	(85)	(141)	(176)	(205)	(599)	(2)
Stock-based compensation	43	77	121	78	74	63
Depreciation and amortization	4	7	9	11	17	22
Net cash from operating activities	(95)	171	(136)	(154)	(463)	180
Purchases of property and equipment	12	24	53	177	141	23
Net cash from investing activities	(241)	(142)	(5)	(96)	(420)	(129)
Proceeds from issuing common stock	250	0	0	0	429	241
Net cash from financing activities	258	11	65	253	871	74
Net change in cash	(78)	41	—	—	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Adaptive Biotechnologies	170	72	(6.4)*	159.6M	53.8 quarters	Q2 FY26 10-QJun 30, 2026
Avadel Pharmaceuticals	80	77	22*	97.7M	—	Q3 FY25 10-QSep 30, 2025
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360	266	57*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47	0	(57)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Innoviva	570	120	52*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Ligand Pharmaceuticals	56	79	(28)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Ocular Therapeutix	599	13	(67)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.